

TEST CHANGE

Interstitial Lung Disease Autoantibody Panel 3001784, ILD PANEL

Snaciman	Requirements:
Specimen	negunements.

Patient Preparation:

Collect: Serum Separator Tube (SST).

Specimen Preparation: Separate from cells ASAP or within 2 hours of collection.

Transfer five 1 mL serum aliquots to ARUP Standard Transport

Effective Date: February 21, 2023

Tubes. (Min: 2.80.5 mL/aliquot)

Transport Temperature: Refrigerated.

Unacceptable Conditions: Hemolyzed, hyperlipemic, icteric, heat-treated or contaminated

specimens.

Remarks:

Stability: Ambient: 24 hours; Refrigerated: 1 weeks; Frozen: 1 month

Methodology: Qualitative Immunoprecipitation/Semi-Quantitative Multiplex

Bead Assay/Qualitative Immunoblot/Semi-Quantitative Enzyme-Linked Immunosorbent Assay/Quantitative

Immunoturbidimetry

Performed: Sun-Sat

Reported: 7-18 days

Note: Antibodies: Ro52, Ro60, Jo-1, PL-7, PL12, EJ, Ku, SRP, OJ,

PM/Scl-100, MDA5, CCP, Scl-70, RA, ANA, NXP-2, RNA

Polymerase III

CPT Codes: 86235 x5; 83516 x7; 84182 x2; 86431; 86200; 86039

New York DOH Approval Status: This test is New York DOH approved.

Interpretive Data:



Effective Date: February 21, 2023

Refer to report.

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Component	Interpretation	
SSA-52 (Ro52)	29 AU/mL or Less	Negative
(ENA) Antibody,	30-40 AU/mL 41	Equivocal
IgG	AU/mL or greater	Positive
SSA-60 (Ro60)	29 AU/mL or Less	Negative
(ENA) Antibody,	30-40 AU/mL 41	Equivocal
IgG	AU/mL or greater	Positive
Scleroderma (Scl-	29 AU/mL or less	Negative
70) (ENA)	30-40 AU/mL 41	Equivocal
Antibody, IgG	AU/mL or greater	Positive
Jo-1 Antibody, IgG	29 AU/mL or less 30-40 AU/mL 41 AU/mL or greater	Negative Equivocal Positive
Cyclic	19 Units or less	Negative Weak
Citrullinated	20-39 Units 40-59	positive Moderate
Peptide (CCP)	Units 60 Units or	positive Strong
Antibody, IgG	Greater	positive
RNA Polymerase III Antibody, IgG	19 Units or less 20-39 Units 40-80 Units 81 Units or greater	Negative Weak positive Moderate positive Strong positive

Reference Interval:

Test Number	Components	Reference Interval
	Rheumatoid Factor	0-14 IU/mL
	Antinuclear Antibody (ANA), HEp-2, IgG	Less than 1:80
	Scleroderma (Scl-70) (ENA) Antibody, IgG	40 AU/mL or less
	SSA-52 (Ro52) (ENA) Antibody, IgG	40 AU/mL or less
	Cyclic Citrullinated Peptide Ab, IgG	0-19 Units
	Jo-1 (Histidyl-tRNA Synthetase) Ab, IgG	40 AU/mL or less
	PL-7 (threonyl-tRNA synthetase) Antibody	Negative
	PL-12 (alanyl-tRNA synthetase) Antibody	Negative
	EJ (glycyl-tRNA synthetase) Antibody	Negative
	Ku Antibody	Negative
	SRP (Signal Recognition Particle) Ab	Negative
	OJ (isoleucyl-tRNA synthetase) Antibody	Negative
	SSA-60 (Ro60) (ENA) Antibody, IgG	40 AU/mL or less
	MDA5 (CADM-140) Ab	Negative
	NXP2 (Nuclear matrix protein-2) Ab	Negative
	PM/Scl 100 Antibody, IgG	Negative
	RNA Polymerase III Antibody, IgG	19 Units or less



Effective Date: February 21, 2023